190 related articles for article (PubMed ID: 9642128)
1. Suppression of type I collagenase expression by antisense RNA in melanoma cells results in reduced synthesis of the urokinase-type plasminogen activator receptor.
Durko M; Brodt P
Biochem Biophys Res Commun; 1998 Jun; 247(2):342-8. PubMed ID: 9642128
[TBL] [Abstract][Full Text] [Related]
2. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.
Nip J; Rabbani SA; Shibata HR; Brodt P
J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755
[TBL] [Abstract][Full Text] [Related]
3. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
[TBL] [Abstract][Full Text] [Related]
4. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
5. The plasminogen-activating system in hepatic stellate cells.
Leyland H; Gentry J; Arthur MJ; Benyon RC
Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
[TBL] [Abstract][Full Text] [Related]
6. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
7. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas.
Pyke C; Kristensen P; Ralfkiaer E; Grøndahl-Hansen J; Eriksen J; Blasi F; Danø K
Am J Pathol; 1991 May; 138(5):1059-67. PubMed ID: 1850957
[TBL] [Abstract][Full Text] [Related]
9. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
10. Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells.
Tavian D; Salvi A; De Petro G; Barlati S
Cancer Gene Ther; 2003 Feb; 10(2):112-20. PubMed ID: 12536199
[TBL] [Abstract][Full Text] [Related]
11. Invasion of extracellular matrix by cultured colon cancer cells: dependence on urokinase receptor display.
Schlechte W; Brattain M; Boyd D
Cancer Commun; 1990; 2(5):173-9. PubMed ID: 2164413
[TBL] [Abstract][Full Text] [Related]
12. Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase.
Ossowski L
Cancer Res; 1992 Dec; 52(24):6754-60. PubMed ID: 1333882
[TBL] [Abstract][Full Text] [Related]
13. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
14. Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines.
Brown PD; Levy AT; Margulies IM; Liotta LA; Stetler-Stevenson WG
Cancer Res; 1990 Oct; 50(19):6184-91. PubMed ID: 2169338
[TBL] [Abstract][Full Text] [Related]
15. Plasmin-catalyzed proteolysis in colorectal neoplasia.
Delbaldo C; Cunningham M; Vassalli JD; Sappino AP
Cancer Res; 1995 Oct; 55(20):4688-95. PubMed ID: 7553650
[TBL] [Abstract][Full Text] [Related]
16. Modulation of the urokinase-type plasminogen activator receptor by the beta6 integrin subunit.
Dalvi N; Thomas GJ; Marshall JF; Morgan M; Bass R; Ellis V; Speight PM; Whawell SA
Biochem Biophys Res Commun; 2004 Apr; 317(1):92-9. PubMed ID: 15047152
[TBL] [Abstract][Full Text] [Related]
17. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
[TBL] [Abstract][Full Text] [Related]
18. Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase.
Kataoka H; DeCastro R; Zucker S; Biswas C
Cancer Res; 1993 Jul; 53(13):3154-8. PubMed ID: 8319225
[TBL] [Abstract][Full Text] [Related]
19. Post-transcriptional regulation of gene expression in the plasminogen activation system.
Montuori N; Rossi G; Ragno P
Biol Chem; 2002 Jan; 383(1):47-53. PubMed ID: 11928821
[TBL] [Abstract][Full Text] [Related]
20. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
